SVB Leerink analyst Joseph Schwartz downgrades Design Therapeutics (NASDAQ:DSGN) from Outperform to Market Perform and announces $6 price target.
SVB Leerink Downgrades Design Therapeutics to Market Perform, Announces $6 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.